MYOMO, INC. SEC Filings

Myomo, Inc. is asking stockholders at its virtual 2026 annual meeting to elect two Class III directors, approve executive pay on an advisory basis, and ratify CBIZ CPAs P.C. as auditor for 2026. Stockholders are also being asked to approve Amendment No. 3 to the 2018 Stock Option and Incentive Plan, increasing shares available under the plan by 1,833,000 shares, and to approve an amendment to the certificate of incorporation to increase the number of authorized shares of common stock to 100,000,000 shares. The agenda includes an advisory stockholder proposal from Horton Fund to declassify the board, authority to adjourn the meeting if needed, and other routine business items.

Myomo, Inc. appointed Joseph M. (Joe) Manko Jr. to its Board of Directors effective May 9, 2026. He will serve as a Class I director until the 2027 annual meeting of stockholders, when he will be eligible for election by shareholders.

Manko, age 60, is Senior Principal of Horton Capital Management LLC, a significant Myomo shareholder, and brings more than 25 years of experience across investment banking, private equity, asset management and corporate strategy. With his appointment, Myomo’s Board now has seven directors.

He will receive the same compensation as other non-employee directors beginning after the 2026 annual meeting, currently an annual cash retainer of $60,000 and an annual grant of restricted stock units with a grant date fair value of $85,000. He has entered into a standard indemnification agreement with the company, and there are no related-party transactions requiring disclosure.

Myomo, Inc. reported Q1 2026 revenue of $10.1 million, up about 3% from a year earlier, as higher average selling prices and international sales offset softer direct-to-patient volume. Gross margin improved to 68.2% from 67.2%, helped by pricing and lower material costs despite higher clinical expenses.

The company recorded a net loss of $3.0 million, narrowed from $3.5 million, and negative operating cash flow of $2.2 million. Adjusted EBITDA loss improved to $2.3 million from $2.8 million as operating expenses were roughly flat, with lower R&D and G&A partly offset by higher selling, clinical and marketing costs tied to advertising and new clinical sales staff.

Myomo ended the quarter with $15.7 million in cash, cash equivalents and short-term investments and working capital of $16.3 million. Long-term debt totaled $12.6 million under a Avenue term loan facility, whose derivative and warrant features produced a non-cash gain from a lower fair value. Management expects current liquidity to fund operations for at least 12 months while focusing on growing recurring MyoConnect and O&P channel revenues and reducing advertising-driven customer acquisition costs.

Myomo, Inc. reported first quarter 2026 revenue of $10.1 million, up 3% from a year earlier, driven by a higher average selling price and a growing mix of recurring patient sources, which rose to 49% of revenue versus 25% in the prior-year quarter.

Gross margin improved to 68.2% and operating expenses fell 1%, narrowing the net loss to $3.0 million, or $0.07 per share. Management expects second quarter 2026 revenue of $10.3 million to $10.8 million and reaffirmed full-year 2026 revenue guidance of $43 million to $46 million, citing a larger backlog and expanding in-network payer access.

Myomo, Inc. is soliciting proxies for its 2026 virtual Annual Meeting of Stockholders to be held June 25, 2026. Stockholders will vote on electing two Class III directors, a non-binding advisory vote on executive compensation, ratifying CBIZ CPAs P.C. as auditor, approving Amendment No. 3 to the 2018 Stock Option and Incentive Plan to add 1,833,000 shares, and amending the certificate of incorporation to increase authorized common stock to 100,000,000 shares.

Only holders of record as of the record date, April 29, 2026, may vote. The board recommends voting FOR the director nominees, executive compensation, the auditor appointment, the plan amendment, and the charter amendment. Registration for the virtual meeting is at www.proxydocs.com/MYO by June 20, 2026.

Myomo, Inc. filed an amendment to its 2025 annual report to add detailed Part III disclosures and correct dates on executive certifications. The update focuses on board structure, committee responsibilities, executive and director compensation, stock ownership and related-party financing transactions, but does not modify previously reported financial results.

The filing describes a six-member classified board with a lead independent director, four standing committees, and a code of business conduct. It details 2025 pay for the CEO, CFO and Chief Medical Officer, including salary, RSUs and performance bonuses, and outlines severance and change-in-control protections. It also discloses major shareholders, insider participation in 2024 equity offerings and fees paid to external auditors.

FEBBO WILLIAM J reported acquisition or exercise transactions in this Form 4 filing.

MYOMO, INC. director William J. Febbo received an equity award covering 45,000 shares of Common Stock as compensation. The Form 4 shows this as a grant of restricted stock units under the company’s 2018 Stock Option and Incentive Plan, with no cash paid per share.

The RSUs vest in full on the first anniversary of the grant date, meaning the entire 45,000-unit award is scheduled to vest after one year if conditions are met. Following this award, Febbo reports beneficial ownership of 45,000 shares/units directly, reflecting a routine, compensation-related equity grant rather than an open‑market purchase or sale.

MYOMO, INC. director William J. Febbo filed an initial Form 3, which is a required statement of beneficial ownership for new insiders. This filing does not report any stock transactions or holdings, indicating it is primarily an administrative disclosure of his insider status.

Myomo, Inc. appointed William “Will” Febbo to its Board of Directors effective April 14, 2026, as a Class II director serving until the 2028 annual meeting, bringing over 30 years of experience in healthcare, financial services, and technology-driven businesses.

As a non-employee director, he was granted 45,000 restricted stock units (RSUs) that vest on the first anniversary of his appointment. He will also receive an annual cash retainer of $60,000 and an additional $85,000 per year in RSUs vesting quarterly. The company highlighted his prior leadership at OptimizeRx, where revenue expanded from $5 million to $92 million with a five-year CAGR of 41%, and his capital markets background as important additions to Myomo’s board.